Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number...Show More

Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number for the common stock will be 42254E302 post-split. The exercise price for the public warrants will be adjusted to $425.00 per share, reflecting the reverse split ratio. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively, although the CUSIP for the public warrants will not change.